Business Overview

Torrent Pharmaceuticals is the flagship pharma company of the Torrent Group (Ahmedabad), operating across branded generics and generics formulations in India, Brazil, Germany, the US and 40+ countries. It holds dominant leadership positions in the chronic therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS) and Gastro-Intestinal (GI), alongside a presence in nephrology, oncology, gynecology, dermatology, pain management, anti-diabetes and VMN (vitamins-minerals-nutrients). Domestic brands include Shelcal, Unienzyme, Tedibar and Ahaglow.

FY26 revenue mix: Branded Generics contribute ~74% of sales (India + Brazil branded business), while Generics (largely regulated markets — US, Europe) contribute the remaining ~26%. The most consequential structural event of FY26 was the completion of the amalgamation of J.B. Chemicals & Pharmaceuticals with Torrent Pharma (NCLT-sanctioned, effective 8 July 2026, share-exchange ratio 51:100, appointed date 21 Jan 2026), which materially expands scale, adds a strong dermatology and Russia/CIS franchise, and lifts the balance sheet — total assets jumped from ₹14,396 Cr (Mar-25) to ₹43,614 Cr (Mar-26).

A second strategic lever is Torrent’s early-mover entry into India’s oral-semaglutide market (brands Sembolic and Semalix), positioning it to capture a share of the fast-growing metabolic/anti-obesity segment at competitive pricing — a segment the company has flagged as a multi-year growth driver alongside the ~₹22,400 Cr of global patent expiries that the broader Indian pharma pack (Sun Pharma, Cipla, Ajanta, Lupin, Torrent) is positioned to benefit from.

Historical Financials

Revenue has compounded steadily, with TTM sales inflated by the JB Chemicals consolidation (33% TTM growth vs 8% 10-year CAGR). Operating margins have expanded consistently from 22% (FY15) to 33% (TTM), reflecting a richer branded-generics mix and cost discipline. Profit growth has been comparatively muted over 10 years (2% CAGR, distorted by a weak FY18-19) but has re-accelerated to 22% over 3 years and 12% over 5 years.

Note: ROCE dropped sharply in the TTM/Mar-26 print (from 27% in FY25) purely as a mechanical effect of the JB Chemicals balance-sheet consolidation (capital employed roughly tripled); underlying operating ROCE on a like-for-like basis remains materially higher.

DCF Valuation

Base FCF of ₹2,386 Cr (FY26) is projected forward over a 10-year explicit period: 15% CAGR for Years 1–5 (JB Chemicals synergy realisation + semaglutide ramp), tapering to 10% for Years 6–10, with a 5% terminal growth rate and a 12% WACC.

The pure-DCF output sits well below CMP, which is typical for a richly-multiple specialty pharma franchise — the market is pricing in optionality (semaglutide, JB Chemicals cross-sell, further M&A) that a base-case FCF model understates. DCF should be read as a valuation floor, not a target.

Relative Valuation & Peer Multiples

Torrent trades at a wide premium — roughly 2.2–3x peer-median P/E and ~4x peer-median P/B — justified historically by superior ROE, a defensible chronic-therapy franchise and best-in-class margins, but the current gap has stretched further than the historical average premium. Applying a 40–55x band (a realistic premium range over the ~28–38x peer median, given Torrent’s superior profitability) to TTM EPS of ₹63.70 yields a relative-valuation range of roughly ₹2,550–3,500 — again below CMP, reinforcing that the stock is pricing in above-consensus execution on the JB Chemicals and semaglutide opportunities.

Asset-Based / NAV

Book value stands at ₹248/share post the JB Chemicals share issuance (equity capital ₹169 Cr + reserves ₹8,219 Cr). At CMP the stock trades at 19.7x book — asset-based valuation is not a binding constraint for a branded pharma franchise where the bulk of economic value resides in brand equity, field-force reach and regulatory dossiers rather than tangible net assets. NAV is presented for completeness only; it is not used in the blended verdict.

Earnings Power Value (EPV)

EPV capitalises normalised TTM operating earnings (assuming no growth) to isolate the value of the existing asset base’s earnings power. Normalised EBIT (TTM operating profit ₹5,191 Cr, less maintenance capex and normalised tax at ~26%) of approximately ₹3,120 Cr, capitalised at the 12% WACC, gives an EPV of roughly ₹26,000 Cr — well below both DCF and market cap, confirming that the bulk of Torrent’s current valuation is a growth/optionality premium rather than a no-growth earnings-power floor.

SOTP

SOTP — which explicitly credits the semaglutide optionality and the JB Chemicals-enhanced derma franchise separately — arrives at ≈₹4,420/share, the closest of all methods to CMP, and is the most representative single method for a business in the middle of a structural re-rating.

Buy Range

CMP ₹4,886 sits at the top edge of the fair-value zone. Fresh accumulation is best staggered on dips toward ₹4,200–4,400 rather than chased at current levels.

Buy Scenario

Sell Range

Sell Scenario

Future Growth

Growth over FY27-30 is likely to be driven by: (1) full-year consolidation and cross-sell synergies from JB Chemicals, particularly in dermatology and the Russia/CIS export corridor; (2) scale-up of the oral semaglutide franchise (Sembolic/Semalix) as India’s obesity/diabetes-care market expands; (3) continued chronic-therapy share gains in CV, CNS and GI domestically; (4) selective US ANDA pipeline execution in a relatively benign US generics pricing environment; and (5) operating leverage as the enlarged combined entity rationalises overlapping field-force and manufacturing costs.

Risks & Catalysts